474 related articles for article (PubMed ID: 23568274)
1. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August KJ; Narendran A; Neville KA
Drugs; 2013 Apr; 73(5):439-61. PubMed ID: 23568274
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Ravindranath Y
Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
[TBL] [Abstract][Full Text] [Related]
3. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for pediatric acute lymphoblastic leukemia.
Graff Z; Burke MJ; Gossai N
Curr Opin Pediatr; 2024 Feb; 36(1):64-70. PubMed ID: 37991046
[TBL] [Abstract][Full Text] [Related]
5. Progress and Prospects in Pediatric Leukemia.
Madhusoodhan PP; Carroll WL; Bhatla T
Curr Probl Pediatr Adolesc Health Care; 2016 Jul; 46(7):229-241. PubMed ID: 27283082
[TBL] [Abstract][Full Text] [Related]
6. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
7. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
[TBL] [Abstract][Full Text] [Related]
8. Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.
Martin A; Morgan E; Hijiya N
Paediatr Drugs; 2012 Dec; 14(6):377-87. PubMed ID: 22880941
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
Ko RH; Ji L; Barnette P; Bostrom B; Hutchinson R; Raetz E; Seibel NL; Twist CJ; Eckroth E; Sposto R; Gaynon PS; Loh ML
J Clin Oncol; 2010 Feb; 28(4):648-54. PubMed ID: 19841326
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
12. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of relapsed or refractory acute lymphoblastic leukemia].
Imai K
Rinsho Ketsueki; 2017; 58(10):1995-2003. PubMed ID: 28978841
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
[TBL] [Abstract][Full Text] [Related]
17. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine in pediatric acute leukemia: current findings and issues.
Hijiya N; Barry E; Arceci RJ
Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining.
Gaynon PS
Curr Hematol Malig Rep; 2007 Jul; 2(3):193-201. PubMed ID: 20425369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
